Navigation

AP & T 1 September 2017

AP&T: CONTENTS LISTING FOR THE 1st SEPTEMBER 2017 ISSUE

The contents listing for the 1st September 2017 issue of Alimentary Pharmacology & Therapeutics is listed below and, as a member of the New Zealand Society of Gastroenterology, you have free access to all these articles when you log-in via the Members’ Area of the NZSG website - www.nzsg.org.nz

Yours sincerely

Roy

Professor R E Pounder
Co-Editor
Alimentary Pharmacology & Therapeutics
website: www.APandT.org
Follow AP&T on Twitter: @APandT

------------------------------------------------------------------------------------------------------

CONTENTS LIST FOR 1st SEPTEMBER 2017 ISSUE OF
ALIMENTARY PHARMACOLOGY & THERAPEUTICS


SYSTEMATIC REVIEW WITH META-ANALYSIS

Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficileinfection (pages 479–493)
M. N. Quraishi, M. Widlak, N. Bhala, D. Moore, M. Price, N. Sharma and T. H. Iqbal


REVIEW ARTICLE

Review article: new treatments in non-alcoholic fatty liver disease (pages 494–507)
S. A. Townsend and P. N. Newsome


POUCH SUGERY FOR ULCERATIVE COLITIS

The outcome of ulcerative colitis patients undergoing pouch surgery is determined by pre-surgical factors (pages 508–515)
H. Yanai, S. Ben-Shachar, L. Mlynarsky, L. Godny, M. Leshno, H. Tulchinsky and I. Dotan


MAGNETIC RESONANCE INDEX FOR FISTULISING CROHN’S DISEASE

The development of a magnetic resonance imaging index for fistulising Crohn's disease (pages 516–528)
M. A. Samaan, C. A. J. Puylaert, B. G. Levesque, G. Y. Zou, L. Stitt, S. A. Taylor, L. M. Shackelton, M. K. Vandervoort, R. Khanna, C. Santillan, J. Rimola, P. Hindryckx, C. Y. Nio, W. J. Sandborn, G. D'Haens, B. G. Feagan, V. Jairath and J. Stoker


IDENTIFICATION OF IRRITABLE BOWEL SYNDROME SUB-GROUPS

Mixture model analysis identifies irritable bowel syndrome subgroups characterised by specific profiles of gastrointestinal, extraintestinal somatic and psychological symptoms (pages 529–539)
A. Polster, L. Van Oudenhove, M. Jones, L. Öhman, H. Törnblom and M. Simrén


8- OR 12-WEEKS OF LEDIPASVIR AND SOFOSBUVIR FOR HCV

Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients (pages 540–548)
M. P. Curry, E. B. Tapper, B. Bacon, D. Dieterich, S. L. Flamm, L. Guest, K. V. Kowdley, Y. Lee, S. Milligan, N. Tsai, Z. Younossi and N. H. Afdhal


INVITED EDITORIALS

Editorial: lean and obese NAFLD—similar siblings (pages 549–550)
T. E. Mellor and D. M. Torres

Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori (pages 550–551)
A. G. Fraser

Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori—authors’ reply (pages 551–552)
Y. S. Jung, E. H. Kim and C. H. Park

Editorial: selective serotonin receptor inhibitors and gastrointestinal bleeding—managing the risk (pages 552–553)
Nimish Vakil

Editorial: depression in the setting of inflammatory bowel disease means we have failed to provide early, effective, psychosocial care (pages 553–554)
L. Keefer

Editorial: depression in the setting of inflammatory bowel disease means we have failed to provide early, effective, psychosocial care—authors’ reply (pages 554–555)
C. Alexakis, S. Kumar, S. Saxena, M. Hotopf and R. Pollok

Editorial: how effective is vedolizumab in the ‘real world’? (pages 555–556)
R. A. Speight and J. C. Mansfield

Editorial: oesophageal dilation in eosinophilic oesophagitis—can and should, but when and how? (pages 556–557)
L. Kia and I. Hirano

Editorial: oesophageal dilation in eosinophilic oesophagitis—can and should, but when and how? Authors’ reply (page 558)
F. J. Moawad, A. J. Lucendo and J. Molina-Infante

Editorial: progress towards a simple tool for screening for hepatic steatosis in the general population (pages 559–560)
J. Gallacher and S. McPherson

Editorial: progress towards a simple tool for screening for hepatic steatosis in the general population – authors’ reply (pages 560–561)
T. C.-F. Yip, A. J. Ma, P.-C. Yuen and G. L.-H. Wong


LETTERS TO THE EDITORS

Letter: role of tenofovir to prevent mother-to-child transmission of hepatitis B virus (pages 562–563)
C.-Y. Zhang, B.-K. Ahir, G-B. Wu, J.-H. Zhong and L.-Q. Li

Letter: role of tenofovir to prevent mother-to-child transmission of hepatitis B virus—authors’ reply (pages 563–564)
Y.-S. Lee, M. H. Hyun, J. H. Kim, J. E. Yeon and K. S. Byun

Letter: a potassium-competitive acid blocker vs a proton pump inhibitor for healing endoscopic submucosal dissection-induced artificial ulcers after treatment of gastric neoplasms (pages 564–565)
H. Ban, M. Sugimoto, T. Otsuka, M. Murata, T. Nakata, H. Hasegawa, M. Fukuda, O. Inatomi, S. Bamba, R. Kushima and A. Andoh

Letter: a potassium-competitive acid blocker vs a proton pump inhibitor for healing endoscopic submucosal dissection-induced artificial ulcers after treatment of gastric neoplasms—authors’ reply (page 566)
T. Kagawa, M. Iwamuro and T. Inaba

Letter: non-alcoholic fatty liver disease and polycystic ovary syndrome—evidence for low vitamin D status contributing to the link (pages 566–567)
Q. Pang, L. Zhou, H. Jin, Z. R. Man and H. C. Liu